Statistics from Altmetric.com
The decision to prescribe antithrombotic therapy in patients with atrial fibrillation (AF) requires a careful assessment of the competing risks of ischaemic stroke and major bleeding, most importantly intracerebral haemorrhage. Non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of haemorrhage and are included in the HAS-BLED score which predicts the 1-year risk of major bleeding in patients with AF receiving oral anticoagulant (OAC) therapy.1 NSAID use has also been associated with an increased risk of stroke and myocardial infarction.2 There is limited data available on the …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.